Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending December 6, 2015
FDA Approves Empliciti in Multiple Myeloma, Indicated as second-line, IV therapy
FDA Approves Ninlaro in Multiple Myeloma, Indicated as second-line, oral therapy
Updated Guidelines on Cutaneous T-Cell Lymphoma, Guidelines cover diagnosis, stratification, and management
Obesity in Acute Myelogenous Leukemia, Comparing survival rates in patients with APL and non-APL AML
FDA Approves Opdivo for Advanced Renal Cell Carcinoma, Second line after prior antiangiogenic therapy
Must reads for theWeek ending November 29, 2015
FDA Approves Darzalex, Immunotherapy indicated for multiple myeloma
Anaphylaxis With Intravenous Iron Therapy, Comparing formulations
Impact of Estrogen on Myeloproliferative Neoplasms, Assessing its effect on essential thrombocythemia and polycythemia vera
Hydroxyurea Therapy in Sickle Cell Disease, Does it affect survival?
Familial Clustering of Multiple Myeloma, Searching for associations with discordant cancers
Must reads for theWeek ending November 22, 2015
FDA Approves Adynovate for Hemophilia A, For on-demand treatment and twice-weekly prophylaxis
Intravenous PEG Asparaginase in Acute Lymphoblastic Leukemia, Comparing it with intramuscular E coli asparaginase
Cytogenetic Markers in Multiple Myeloma, Studying the effects of newer therapies on prognostication
Next Generation Sequencing of Resistance Mutations, A new tool in Ph+ leukemias
FDA Approves Cotellic/Zelboraf Combination, Used in treatment of unresectable or metastatic melanoma
Must reads for theWeek ending November 15, 2015
ASCO Revises Guidelines on Antiemetics, Committee issues evidence-based update
Conditioning Following AlloHCT, Comparing myeloablative to reduced-intensity conditioning
Gene Expression Profiling in Multiple Myeloma, Defining high-risk status
Age and Incidence in Chronic Myeloid Leukemia, Studying geographic differences
ASCO Revises Guidelines on Antiemetics, Committee issues evidence-based update
Must reads for theWeek ending November 8, 2015
Variant Allele Frequency in MDS, Do gene mutations have prognostic value?
Stem-Cell Transplantation in Older Patients, Studying survival in patients aged > 60 years
Absolute Lymphocyte Count After Bone Marrow Transplantation, Evaluating prognostic value
Sex Differences in AML Survival, Whom does nature favor?
Resources Available to Patients With Hemophilia, Surveying patients about HTC quality and gaps